June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Development and Characterization of a 3-Dimensional Human Corneal Full Thickness Tissue Model
Author Affiliations & Notes
  • Yulia Kaluzhny
    MatTek Corporation, Ashland, MA
  • Laurence d’Argembeau-Thornton
    MatTek Corporation, Ashland, MA
  • Helena Kandarova
    MatTek Corporation, Ashland, MA
  • Pat Hayden
    MatTek Corporation, Ashland, MA
  • Mitch Klausner
    MatTek Corporation, Ashland, MA
  • Footnotes
    Commercial Relationships Yulia Kaluzhny, MatTek Corporation (E); Laurence d’Argembeau-Thornton, MatTek Corporation (E); Helena Kandarova, MatTek Corporation (E); Pat Hayden, MatTek Corporation (E); Mitch Klausner, MatTek Corporation (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3292. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yulia Kaluzhny, Laurence d’Argembeau-Thornton, Helena Kandarova, Pat Hayden, Mitch Klausner; Development and Characterization of a 3-Dimensional Human Corneal Full Thickness Tissue Model. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3292.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

The FDA and other regulatory agencies require ocular irritation testing of ophthalmologic pharmaceuticals and many consumer products. Although widely used, animal testing has limitations due to interspecies differences, variability, high cost, and animal welfare issues. A highly reproducible, cost effective, human cell-based in vitro corneal tissue model would be of high utility for ocular irritation testing and ophthalmic drug development.

 
Methods
 

Using primary culture and state of the art tissue engineering techniques, we have developed a human corneal full thickness (CFT) tissue model which includes epithelial, stromal, and endothelial layers. This model has been characterized in terms of histology and by testing a battery of test articles (TA, n=65) spanning the range from ocular corrosives and severe irritants to non-irritants (NI). In vivo irritancy levels were obtained from a published database and in vitro effects were determined using the MTT tissue viability assay and transepithelial electrical resistance (TEER) measurements.

 
Results
 

Using a tissue viability cutoff of 50%, the ocular CFT (OCFT) model was able to detect irritants with 100.0% sensitivity and non-irritants with 75.0% specificity (overall accuracy = 87.7%). In addition, the OCFT model was used to assess tissue recovery following exposure to increasing concentrations of surfactants and TA spanning the range of irritancy. Significant recovery at 24 and 48 hours was observed for NI chemicals. For the same 65 TA, an ex vivo assay, the Bovine Corneal Opacity and Permeability (BCOP), had 87.9%, 68.8%, and 78.5% assay sensitivity, specificity, and accuracy, respectively.

 
Conclusions
 

The OCFT model will address the needs of ophthalmic and other formulators who need to screen their products for irritancy and efficacy. Similar to other in vitro assays, high levels of reproducibility at a low cost are anticipated. The OCFT model will facilitate the development and testing of ophthalmic pharmaceuticals and allow for basic studies related to corneal physiology, wound repair, and pathologies.

 
 
Histological cross-section: Formalin fixed, paraffin embedded, H&E stained cross-section of OCFT tissue model (4X). 1. Corneal epithelium (10X); 2. Stroma with embedded keratocytes; 3. Endothelial layer (20X); 4. Micorporous membrane; 5. Air-liquid interface; 6. Culture medium fed through the membrane.
 
Histological cross-section: Formalin fixed, paraffin embedded, H&E stained cross-section of OCFT tissue model (4X). 1. Corneal epithelium (10X); 2. Stroma with embedded keratocytes; 3. Endothelial layer (20X); 4. Micorporous membrane; 5. Air-liquid interface; 6. Culture medium fed through the membrane.
 
Keywords: 620 ocular irritancy/toxicity testing • 503 drug toxicity/drug effects • 765 wound healing  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×